Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

James F. Polewaczyk net worth and biography

James Polewaczyk Biography and Net Worth

EVP of IDEXX Laboratories

Mr. Polewaczyk has been an Executive Vice President and the Chief Commercial Officer of IDEXX since January 2020. After joining IDEXX as a Corporate Vice President in February 2007, he served in various leadership roles. From June 2014 to January 2020, he led the company’s North American Companion Animal Group Commercial Operations. Prior to this, from July 2012 to June 2014, he led the company's Companion Animal Group Reference Laboratories and Telemedicine lines of business, and from 2007 to 2012, he led the company’s Rapid Assay, Digital Imaging and Telemedicine business lines. Prior to joining IDEXX, from 2001 to 2006, Mr. Polewaczyk was General Manager of the Medical Consumables and Sensors business at Philips Medical Systems, a subsidiary of Royal Philips Electronics, the Netherlands, a healthcare, lifestyle and lighting technologies company. Prior to that, Mr. Polewaczyk spent 15 years at Hewlett-Packard Corporation, a technology company, in a variety of senior marketing and medical technology product development roles. Mr. Polewaczyk holds a bachelor’s degree in electrical engineering from Worcester Polytechnic Institute and an M.B.A. from Boston University.

What is James F. Polewaczyk's net worth?: The estimated net worth of James F. Polewaczyk is at least $4.14 million as of December 7th, 2023. Mr. Polewaczyk owns 10,050 shares of IDEXX Laboratories stock worth more than $4,143,213 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Polewaczyk may own. Learn More about James F. Polewaczyk's net worth.
How do I contact James F. Polewaczyk?: The corporate mailing address for Mr. Polewaczyk and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at [email protected]. Learn More on James F. Polewaczyk's contact information.
Has James F. Polewaczyk been buying or selling shares of IDEXX Laboratories?: James F. Polewaczyk has not been actively trading shares of IDEXX Laboratories during the last ninety days. Learn More on James F. Polewaczyk's trading history.
Who are IDEXX Laboratories' active insiders?: IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), George Fennell (SVP), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.
Are insiders buying or selling shares of IDEXX Laboratories?: During the last year, insiders at the sold shares 5 times. They sold a total of 44,068 shares worth more than $25,124,750.88. The most recent insider tranaction occured on November, 27th when Director Sophie V Vandebroek sold 344 shares worth more than $144,631.36. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.
Information on this page was last updated on 11/27/2024.

James F. Polewaczyk Insider Trading History at IDEXX Laboratories

James F. Polewaczyk Buying and Selling Activity at IDEXX Laboratories

IDEXX Laboratories Company Overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Today's Range

Now: $412.26

$404.36

$418.26

50 Day Range

MA: $433.90

$406.92

$478.00

2 Week Range

Now: $412.26

$398.50

$583.39

Volume

1,122,179 shs

Average Volume

516,185 shs

Market Capitalization

$33.76 billion

P/E Ratio

39.76

Dividend Yield

N/A

Beta

1.37

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.